referral-south-africa — conflicts

Conflict: [Kannenberg et al., SAFP 2020] recommends TCIs first-line for mild–moderate flares on sensitive sites and considers pimecrolimus safe <2 y. [NICE CG57 / TA82, 2004–2007] says TCIs are not first-line, are for ≥2 y, specialist-initiated. Unresolved. (See South African Eczema Guidance)

Conflict: [SAHPRA Dupixent PIL, 13 May 2024] registers dupilumab for AD from 6 years; safety <6 “not yet known”. [FDA label 2022+ / EMA EPAR] license from 6 months. Unresolved — later SAHPRA amendment not checked. (See South African Eczema Guidance, Dupilumab)

Conflict: [Staab et al., BMJ 2006] calls age-related education “significantly more effective” than usual care. [Ersser et al., Cochrane 2014] notes the objective-SCORAD CIs (e.g. 4.2, 1.7–6.8 in under-7s) do not exceed the 8.2-point MCID. Unresolved. (See Eczema Education Programmes)